7/2020 - Texas A&M AgriLife licenses mAb-factory technology to improve their development of innovative antibiotic strategies
The Center for Phage Technology (CPT) at Texas A&M AgriLife is a world leader in advancing the application of phage to combat bacterial infections and will now use our ultra-large gene library and selection technologies.
12/2016 - Antibody discovery and engineering services provided by YUMAB
Human antibody discovery and antibody engineering services based on our antibody phage display technologies are now provided by our partner Yumab GmbH (www.yumab.com). Please contact Yumab. directly for the generation of therapeutic antibodies for your clinical pipeline.
12/2016 - Crystal structure of a human antibody from library HAL9
Sundberg and Sandra Postel (University of Maryland) presented the X-ray
crystal structure of a human immunglobulin Fab fragment binding to
flagellar capping protein (FliD, UniProtKB: Q9K3C5) from Pseudomonas aeruginosa. The Fab fragment was derived by
from the original scFv antibody fragment isolated by phage display from
the HAL9 naive human monoclonal antibody library in the framework of an
academic reserach collaboration. FliD is responsible for the adhesion of
the bacterium to mucin, which is the initial event in colonization by
this organism of the airways of cystic fibrosis patients.
11/2016 - Therapeutic human antibody pipeline news
CALYPSO Biotech SA, Switzerland (www.calypsobiotech.com)
reports the successful generation of Anti-MMP-9 (Matrix metalloprotease
9) antibodies for their therapeutic pipeline by using our technology
platform for the selection of human monoclonal antibodies. MMP-9 is a
promising target for the treatment of Inflammatory Bowel Disease.
Reference: Goffin L, Fagagnini S, Vicari A,
Mamie C, Melhem H, Weder B, Lutz C, Lang S, Scharl M, Rogler G, Chvatchko Y,
Hausmann M. Anti-MMP-9 Antibody: A Promising Therapeutic Strategy for Treatment
of Inflammatory Bowel Disease Complications with Fibrosis. Inflamm Bowel Dis.
2016 Sep;22(9):2041-57. - Link to publication